SCHEMBL563141

SCHEMBL563141

CCCCCc1nc(NCc2ccc(OC)cc2)c(N)c(NCC2CCOCC2)c1Cc1ccc(OC)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 1/20 0.38
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
PDE2A O00408 2/20 0.36
TLR7 Q9NYK1 2/20 0.35
CYP2D6 P10635 2/20 0.35
HRH1 P35367 1/20 0.35
KCNH2 Q12809 1/20 0.35
PDE6D O43924 1/20 0.35
PDE6A P16499 1/20 0.35
PDE6G P18545 1/20 0.35
PDE6B P35913 1/20 0.35
PDE6C P51160 1/20 0.35
PDE6H Q13956 1/20 0.35
PDE10A Q9Y233 1/20 0.35
APP P05067 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL563593 0.86 EGFR (0.45) PRKCQPDE4APDE4BPDE4CPDE4D
SCHEMBL563155 0.81 PDE4A (0.45) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL562962 0.80 TLR7 (0.43) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL563165 0.79 PGK1 (0.41) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL563260 0.78 TLR7 (0.42) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL562174 0.77 APP (0.42) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL563543 0.73 MAPT (0.48) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL562853 0.67 EGFR (0.46) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL563105 0.67 EGFR (0.54) TLR7MAPTSMN1; SMN2ALDH1A1ATM
SCHEMBL563545 0.66 EGFR (0.51) CYP2D6MAPTSMN1; SMN2ALDH1A1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035209-A1 Hydroxy Substituted 1H-Imidazopyridines and Methods PFIZER INC. (US) 2012-02-09 US disclosed
US-20100152230-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. 2010-06-17 US disclosed
EP-1924581-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS Pfizer, Inc. (US) 2008-05-28 EP disclosed
WO-2007028129-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS PFIZER INC. (US) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152230-A1 HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS IL4, IL2, IL4I1 PRKCQ 3501/4885PDE4A 687/4885PDE4B 1214/4885
US-20120035209-A1 Hydroxy Substituted 1H-Imidazopyridines and Methods IL2, IL4, IL4I1 PRKCQ 3453/4885PDE4A 782/4885PDE4B 1357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.